Preview Mode Links will not work in preview mode


Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients.  In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.

Popular Topics

  • Virtual and digital health
  • Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
  • Value-based healthcare 
  • Precision and stratified medicine
  • Integration of digital technology into existing workflow and procedures 
  • Next-generation immuno, cell, and gene therapies
  • Vaccines
  • Biomarkers, sequencing, and imaging
  • Rare diseases
  • MedTech and medical devices
  • Clinical trials
  • Addressing Social Determinants of Health
  • Treating chronic conditions like obesity and pain
  • Clinician and staff burnout

The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors. 


Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.

Empowered Patient Solutions

Dec 30, 2021

Dr. Dan Gold is the President and CEO of MEI Pharma and is tackling non-Hodgkin's B cell lymphoma to bring a therapy to patients minimizing the toxicities that are associated with current treatments. Their drug candidate zandelisib is a P13K delta inhibitor. It is being studied in lymphoma in B cells to determine if this is a way to block signaling and diminish the malignant capacity of the B cell.

Dan explains, "We sort of think of lymphoma in two flavors. it's either a more chronic disease, or it's a more aggressive disease, and then there is sort of a spectrum that spans that. In the less aggressive, we call it indolent diseases, the patients will live with these cancers for many, many years. "

"So for the cancers that we treat most commonly or that we're studying most commonly, they're more of the indolent variety. It is interesting because the fact that it's indolent, the patients will respond to therapies. But, eventually, the efficacy of that therapy will wane, and they'll need something else. But there are a number of options that can be staged over the years, again, to keep that cancer at bay, or at least minimally invasive and minimally problematic for many, many years. That's the area that we're focusing all of our energies on currently."

"What we have done, and what we have strived to do is to diminish those toxicities so that the patient will stay on the drug as long as possible. So what we've kind of pioneered for this class of drugs, because of the properties of zandelisib, is that we initially give the patient the drug on a daily basis for a couple of months to get that tumor at bay and shrink it as much as we can."

@MEI_Pharma $MEIP #Lymphoma #BloodCancer #P13K #P13KDelta #OptimizedDosing #SanDiego

Listen to the podcast here

MEI Pharma